What records are connected here?
- Evidence lanes
- 2
- Source years
- 4
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved1,3Evidence: Smaller human trialsLiver
Also called HM12525A, JNJ-645651111
Efinopegdutide is an experimental agonist of both the GLP-1 and glucagon receptors, built from an oxyntomodulin analogue linked by polyethylene glycol to part of a human antibody, studied for fatty liver disease.1,2 In a 24-week phase 2a trial of 145 people with non-alcoholic fatty liver disease, it cut liver fat by 72.7% on average, compared with 42.3% for semaglutide.2 No FDA approval is reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.1,3,5
| What it is | An oxyntomodulin analogue conjugated by a polyethylene glycol linker to a human IgG4 Fc fragment, also coded HM12525A and JNJ-64565111, according to FDA’s substance registry.1 |
|---|---|
| FDA status | No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list it.1,3 |
| Human evidence | A 24-week phase 2a randomized, open-label trial in 145 people with non-alcoholic fatty liver disease, compared with semaglutide.2 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Efinopegdutide is a modified analogue of the hormone oxyntomodulin joined by a polyethylene glycol linker to the Fc portion of a human IgG4 antibody, according to FDA’s substance registry.1
The registry also records the codes HM12525A and JNJ-64565111.1
FDA’s substance registry records it as an agonist of the GLP-1 receptor and the glucagon receptor.1
The trial authors write that GLP-1-driven weight loss can reduce liver inflammation, and that acting on the glucagon receptor may also reduce liver fat directly by increasing fat burning and reducing fat production in the liver.2
In a 24-week open-label trial, 145 people with at least 10% liver fat were randomly assigned to efinopegdutide or semaglutide. Liver fat fell by 72.7% on average with efinopegdutide and 42.3% with semaglutide, a significant difference.2
Weight fell by 8.5% and 7.1% respectively, a difference that was not significant. Side effects, mainly gastrointestinal, were slightly more common with efinopegdutide.2
Evidence-strength label: Smaller controlled human trials. How this label is assigned
None of the sources reviewed here reports an approval of efinopegdutide by FDA.1,3
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list efinopegdutide.3
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Efinopegdutide is not among them.4,5
Whether reducing liver fat translates into less liver inflammation and scarring, which the 24-week trial measured only by imaging.2
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Efinopegdutide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Efinopegdutide are a bounded selection, not every registration or paper about Efinopegdutide. For the years before Efinopegdutide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Efinopegdutide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Efinopegdutide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
No FDA approval reported; studied in clinical trials. Published evidence is a 145-person phase 2a trial. Efinopegdutide is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
No FDA approval reported; studied in clinical trials. Published evidence is a 145-person phase 2a trial. Efinopegdutide is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 9, 2026
Efinopegdutide: a step towards precision in MASH therapy?↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
Efinopegdutide: a step towards precision in MASH therapy?↗Source date November 9, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT06465186↗Source date September 21, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT06482112↗Source date June 1, 2026PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
9 of 9 selected trial records include at least one phase value; 9 of 9 include a status value in the retained structured contract.
1 of 1 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT03235219 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was efinopegdutide.
PeptideScanner retained ClinicalTrials.gov record NCT03546205 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was efinopegdutide.
PeptideScanner retained ClinicalTrials.gov record NCT03586843 at 2026-11-16T17:46:45.897Z. Its registry update date was 2019-04-16, and PeptideScanner's reviewed identity mapping was efinopegdutide.
1 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Selected records span April 16, 2019 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 43003104 in Lancet (London, England) as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug efinopegdutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06465186 at 2026-11-16T17:46:45.897Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was efinopegdutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06482112 at 2026-11-16T17:46:45.897Z. Its registry update date was 2026-06-01, and PeptideScanner's reviewed identity mapping was efinopegdutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06052566 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-10-22, and PeptideScanner's reviewed identity mapping was efinopegdutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03235219 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was efinopegdutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03546205 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was efinopegdutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06701305 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-02-26, and PeptideScanner's reviewed identity mapping was efinopegdutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06836037 at 2026-11-16T17:46:45.897Z. Its registry update date was 2025-02-21, and PeptideScanner's reviewed identity mapping was efinopegdutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03606057 at 2026-11-16T17:46:45.897Z. Its registry update date was 2020-03-03, and PeptideScanner's reviewed identity mapping was efinopegdutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03586843 at 2026-11-16T17:46:45.897Z. Its registry update date was 2019-04-16, and PeptideScanner's reviewed identity mapping was efinopegdutide.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
Journal of Hepatology · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026